Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Interferon Beta-1a	448
Overall Study	STARTED	Ozanimod 0.5 mg	451
Overall Study	STARTED	Ozanimod 1 mg	447
Overall Study	Safety Population	Interferon Beta-1a	445
Overall Study	Safety Population	Ozanimod 0.5 mg	453
Overall Study	Safety Population	Ozanimod 1 mg	448
Overall Study	COMPLETED	Interferon Beta-1a	412
Overall Study	COMPLETED	Ozanimod 0.5 mg	425
Overall Study	COMPLETED	Ozanimod 1 mg	418
Overall Study	NOT COMPLETED	Interferon Beta-1a	36
Overall Study	NOT COMPLETED	Ozanimod 0.5 mg	26
Overall Study	NOT COMPLETED	Ozanimod 1 mg	29

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02294058/flow